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ABSTRACT 
BACKGROUND AND OBJECTIVE  
Breast pain or mastalgia is one the most common clinical 
problems with which women approach surgical outpatient 
department. It is imperative to have a clear picture regarding the 
epidemiological, pathological and radiological factors pertaining to 
this problem. 
METHODS  
Between July 2015 and September 2015, 100 patients with 
mastalgia who got consultation as outpatient or inpatient in 
Institute of General Surgery, Rajiv Gandhi Government General 
Hospital, Chennai were subjected to evaluation and management as 
per treatment guidelines derived from recent systematic review. 
Data was collected and analyzed. 
RESULTS  
Majority of the patients presented with fear of cancer rather 
than debilitating pain which would hinder with their activities of 
daily life. Conservative management with analgesics and breast 
support was useful in most of the patients. A subset of the patients 
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presented with pathologies requiring surgical treatment and they 
were offered those treatments and results evaluated.    
INTERPRETATION AND CONCLUSION  
Patient education and availability of quality radiological and 
pathological services are crucial in the management of patients with 
mastalgia in alleviating the fear of cancer among these women. 
Reassurance and appropriate medical and surgical treatment 
according to the cause of breast pain can reduce the morbidity and 
improve the outcome of the disease.  
KEY WORDS 
Mastalgia, breast pain, analgesics, breast support, cancer fear.  
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INTRODUCTION 
Mastalgia is the most common breast symptom in patients 
attending a breast clinic [1]. Approximately 60 to 70 % of women 
experience some degree of breast pain at some stages of their lives, 
and in 10 to 20 % of cases, it is severe [2, 3]. The two most 
common concerns of patients presenting with mastalgia are: the 
fear of breast cancer and the presence of severe pain affecting 
quality of life. The majority of patients with mastalgia can be 
managed with reassurance and simple drugs. The most important 
responsibility of the breast specialist is to convincingly rule out 
cancer and assiduously reassure the patient. Mastalgia is often 
associated with breast nodu-larity that may be tender or without a 
discrete lump. Some amount of breast nodularity and mastalgia are 
found in normal population [3, 4]. 
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OBJECTIVES 
The purpose of this dissertation is to analyse the various 
epidemiological, clinical, radiological and pathological facets of 
breast diseases presenting as mastalgia in women in a tertiary 
referral institute in south india  . 
The study period is between July 2015 to September  2015. 
1) To evaluate and manage the different causes of breast pain 
according to recently published evidence. 
2) To describe the breast pathologies we treat  and compare 
outcomes. 
3) To identify measures to decrease anxiety and morbidity 
attributed to this clinical problem. 
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REVIEW OF LITERATURE 
Mastalgia is the most common breast symptom in patients 
attending a breast clinic [1]. Approximately 60 to 70 % of women 
experience some degree of breast pain at some stages of their 
lives, and in 10 to 20 % of cases, it is severe [2, 3]. The two most 
common concerns of patients presenting with mastalgia are: the fear of 
breast cancer and the presence of severe pain affecting quality of 
life. The majority of patients  with mastalgia can be managed with 
reassurance and simple drugs. The most important responsibility 
of the breast specialist is to convincingly rule out cancer and 
assiduously reassure the patient. Mastalgia is often associated 
with breast nodularity that may be tender or without a discrete  
lump. Some amount of breast nodularity and mastalgia are found in 
normal population [3, 4]. 
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CLASSIFICATION OF BREAST PAIN 
CYCLICAL MASTALGIA  
Cyclical breast pain occurs 1 to 2 weeks prior to menses. The 
pain is commonly felt diffusely and bilaterally, with some radiation to 
the upper arm and axilla. It can be more severe in one breast than the 
other and it is relieved by the onset of menstrual flow. These patients 
are usually aged between 30 and 40. Cyclical mastalgia may have 
spontaneous resolution in up to 22 % of patients and persists in up 
to 65 % of patients after treatment [4]. However, it can resolve with a 
hormonal event such as pregnancy or menopause, and because of this, 
it is postulated that cyclical mastalgia is due to hormonal stimulation 
of breast parenchyma particularly at the end of the luteal phase of the 
menstrual cycle [5]. For many, it may be a lifelong suffering to 
abate at menopause if left untreated [4]. 
Noncyclical Mastalgia It is usually unilateral and localized to 
a particular quadrant of the breast. Patients are usually older, in 
their 40s or 50s, and are often perimenopausal [5]. There are 
several causes of noncyclical mastalgia including cysts, periductal 
mastitis, stretching of Cooper’s ligaments, traumatic fat necrosis, 
Mondor’s disease, diabetic mastopathy, and neoplasia [3, 5]. 
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Noncyclical mastalgia can resolve without treatment in up to 50 % 
of cases but can also be more difficult to treat [3]. 
Finally, non-breast pain can mimic mastalgia. Common 
causes of chest wall pain include costochondritis (Teitze’s disease), 
referred nerve root pain as in cervical spondylitis, and herpes 
zoster. Non-chest wall pain can arise from diverse causes such as 
ischemic heart disease, biliary pain, and peptic ulcer [5, 6]. 
ETIOLOGY OF MASTALGIA 
ENDOCRINE ABNORMALITIES 
Three main theories have emerged regarding etiology of 
painful nodular breasts: 
a. Increased estrogen secretion from the ovary 
b. Deficient progesterone production 
c. Hyperprolactinemia 
The studies of serum hormones levels do not support the first 
two theories, as hormonal levels were found to be similar in 
patients and controls [7]; however, study from France showed a 
significantly depressed level of luteal progesterone, thus supporting 
the second theory [8]. 
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Peters et al. found that the patients with mastalgia had a 
significantly greater rise in prolactin compared with the controls 
[9]. A study at Cardiff Mastalgia Clinic also reported a rise in 
stimulated prolactin level in women with mastalgia [10]. 
WATER RETENTION 
At the Cardiff Mastalgia Clinic, the total body water was 
estimated using radioactive water (D2O) in mastalgia patients and 
asymptomatic normal women. The results showed that there were 
no significant differences in water gain between the 5th and 25th 
days of menstrual cycle in mastalgia patients compared to normal 
controls [10]. So it was concluded that simple retention of body 
water was not associated with breast pain [11]. 
PSYCHONEUROSIS 
Astley Copper suggested that mastalgia patients were 
neurotic. Using Middlesex Hospital Questionnaire (MHQ), psycho- 
neurotic profiles of 300 patients with mastalgia'(cyclical and 
noncyclical) and 156 patients with varicose veins were tested. The 
MHQ scores of mastalgia patients were significantly lower than 
those of psychiatric patients, thus showing no component of 
psychoneurosis in occurrence of mastalgia [12]. 
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CAFFEINE AND METHYLXANTHINE 
It is suggested that overstimulation of breast cells may occur 
due to interference with adenosine triphosphate degradation by 
methylxanthine. Minton et al. reported that caffeine restriction 
produced improvement in symptoms; however, these studies were 
uncontrolled [13]. Subsequent random- ized trials have failed to 
demonstrate a benefit of caffeine restriction in relieving mastalgia 
[14]. 
MISCELLANEOUS FACTORS 
Peters et al. observed that breast pain was associated 
positively with degree of ductal dilatation, as demonstrated by 
ultrasound scan [15]. 
CLINICAL ASSESSMENT AND INVESTIGATIONS 
A history and examination will point to the diagnosis in most 
cases. A prospective pain diary is extremely helpful, as patient ’s 
recollection of events can be inaccurate and incomplete. 
Investigations A mammogram should be performed for 
women aged 35 years and above. Ultrasound examination is helpful 
if there is a clinical palpable abnormality or if the patient presents 
with localized noncyclical pain. Ultrasound of the whole breast may 
be performed depending on the expertise and resources available to 
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the treating physician. Frequently reported cysts and other benign 
lesions on X-ray mammogram and ultrasound should not worry the 
patients unnecessarily in the absence of a discretely palpable lump. 
Other investigations may be necessary to complete the ―triple test‖ 
if a lump is present such as image-guided breast biopsy of any 
suspicious lesion or cytology of serous or bloody nipple discharge.  
MANAGEMENT 
The following measures can be applied to both noncyclical 
and cyclical mastalgia. 
DAILY BREAST PAIN CHARTING 
Patients are explained about hormonal changes with men- 
struation and its relation with mastalgia and requested to record 
their daily pain experience on a chart (Fig. 1). The days with 
menses are marked with letter ―P‖ (Fig. 2). 
The severity of pain is also noted on a visual analogue scale 
(VAS, also called visual linear analogue). VAS is usually a 
horizontal line, 10 cm in length, anchored by word descriptors at 
each end (Fig. 3). The patient marks on the line below, the point 
that they feel represents their perception of pain. The VAS score is 
determined by measuring in millimeter from the left hand end of 
the line to the point that the patient marks. On this VAS, the 0 
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indicates no pain and 10 indicate very severe excruciating pain in 
the breast.  
Most mastalgia experts consider any pain of ≥3 on a VAS of 
0 to 10 to be significantly severe to require therapy [16]. 
Reassurance 
A woman who has no abnormality detected on clinical 
assessment and triple test can be reassured that the possibility of an 
undetected breast malignancy is less than 5 %. Majority of women 
feel comfortable and at ease once cancer is ruled out [5]. 
Physical measures: It is estimated that up to 70 % of women 
wear improperly fitted bras. Thus, it is important to ensure that the 
patient is fitted with sufficiently sup- portive and well-fitting 
brassiere [17]. It is especially useful in women endowed with large 
mammary glands. In a randomized trial of 200 women with 
mastalgia, 100 women received treatment with danazol and the 
other 100 were asked to wear sports brassieres for 12 weeks. The 
danazol group had 58 % relief of symptoms (with drug side effects 
in 42 %), while in the brassiere group, 85 % had relief of symptoms 
with improved lifestyle [17]. Sports garments relieve pain by 
reducing the over- stretching of the Cooper’s ligament. 
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Relaxation techniques: Four weeks of relaxation therapy was 
reported to provide relief in 60 % of patients [18]. 
Vitamins: There is no convincing evidence to support the use 
of vitamins in treatment of mastalgia; however, vitamin B1, B6, 
and E are all used by clinicians. These have no role and should not 
be misused [23]. A recent meta-analysis described that long-term 
use of vitamin E may increase risk of hemorrhagic stroke (RR= 
1.22; 95 % confidence interval 1 to 1.48; p=0.045) [19]. 
Evening primrose oil: Although evening primrose oil has 
been used in past with some success in a few trials [20, 21], meta-
analysis revealed that the benefit in pain reduction is similar to that 
achieved by placebo [22]. But some centers still prefer to use 
evening primrose oil for breast pain. 
SIMPLE MEDICATIONS 
Nonsteroidal anti-inflammatory medications can be effective 
in up to 80 % of women and their usefulness is often 
underestimated. Diclofenac gel applied as local massage to painful 
areas of breast has been found to be more effective than placebo gel 
and ibuprofen gel in randomized trials [23]. Colak studied the 
effects of topical diclofenac gel on cyclic and noncyclical mastalgia 
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in 108 patients: 60 with cyclic (group I) and 48 with noncyclical 
(group II). Patients within each group were randomized to 
diclofenac gel or placebo cream, three times daily for 6 months. 
The pain score decreased significantly in diclofenac gel group 
compared to placebo. The benefit was seen in both cyclical and non- 
cyclical breast pain. No side effect was reported in any group [23]. 
FIG. 1 A DAILY BREAST PAIN CHART 
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FIG. 2 A TYPICAL PAIN PATTERN OF CYCLICAL 
MASTALGIA WITH PREMENSTRUAL  EXACERBATION 
 
HORMONE REPLACEMENT THERAPY AND BREAST PAIN 
The response of oral contraceptives and hormone replace- 
ment therapy (HRT) on breast pain is variable in differ- ent 
individuals. While some women may develop breast pain on 
starting oral pills or HRT, others may feel relieved of their 
mastalgia with these medications. Stud- ies of low-dose oral 
contraceptives (20 μg ethinyl estra- diol) have found no increase in 
breast symptoms compared with placebo [24]. 
Topical, oral, and parenteral progestogens have been studied 
for treatment of breast pain with variable results. The oral 
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progestogens, lynestrenol, and promegestone          administered 
during the luteal phase significantly improved breast pain in 66 to 
80 % of women [25, 26]. No systematic review or RCTs could be 
found to assess the effects of HRT for treating mastalgia. HRT 
usually increases the risk of breast pain; hence, no trial on HRT for 
therapy of mastalgia has been conducted. Due to the risk of side 
effects, hormonal medications should only be used for 2 to 6-month 
periods. 
Tamoxifen: Tamoxifen at a dose of 10 mg daily is reported to 
relieve cyclical mastalgia in 70 to 90 % and noncyclical mastalgia 
in 56 % of cases. Side effects at this low dose for 3 months are 
minimal and include irregular periods and hot flushes. Tamoxifen is 
the drug of choice for mastalgia in most breast clinics in the West 
[27]. The patient must be told that tamoxifen is not being given for 
cancer. 
Centchroman: Centchroman or ormeloxifene (marketed as 
SAHELI by Hindustan latex company India) is a nonsteroidal 
antiestrogen agent. It is used as ―once a week contraceptive pill‖ 
which selectively binds with estrogen receptor in the breast and 
endometrium. This molecule was developed at the Central Drug 
Research Institute, Lucknow. At the All India Institute of Medical 
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Sciences breast clinic, centchroman has been used for control of 
mastalgia. Initially a dosage of 30 mg on alternate days was 
employed in 19 patients. The frequency of dosage was later 
increased to once daily, as there were no major side effects seen 
and some women missed doses with alternate day therapy. Hence to 
improve compliance and effect, in latter part of study, it was given 
as 30 mg once a day to 23 patients.  
In a randomized trial of 81 patients (42 randomized to 
centchroman and 39 to danazol), combining both alternate and daily 
dosage, centchroman was found to have response of 89.7 % 
(response being defined as number of women achieving reduction 
of pain to less than or equal to 3 on VAS of 0 to 10) whereas cases 
receiving danazol achieved a response of 69.4 % at 12 weeks of 
therapy [28]. 
A greater proportion of women in centchroman group 
continue to enjoy pain-free life even after the drug was stopped, 
suggesting a longer carry over effect. It is also cheaper than 
tamoxifen [29]. Moreover, there are no reports of endometrial 
carcinoma or thromboembolic side effects with long-term use of 
centchroman as compared to tamoxifen [30]. Patients should be 
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actively informed that centchroman is not being used for 
contraceptive purpose. 
FIG. 3 A “VISUAL LINEAR ANALOGUE SCALE FOR 
MEASURING PAIN 
 
Danazol: It is an antigonadotrophin agent. Danazol is a 
testosterone derivative and has mild androgenic effect [31]. Current 
practice in India is to start treatment at 50 mg once daily and then 
increase to 50 mg twice daily if the response is not complete. The 
maintenance dose should be given for at least 3 months [32]. In the 
West, the recommendation is to use a maintenance dose of 100 mg 
daily or alternate days. The common side effects with danazol are 
hair growth, weight gain, and menstru- al irregularities; hence its 
use should be reserved for cases of severe mastalgia who have 
failed on 3–6 months of tamoxifen and centchroman treatment. It is 
contra- indicated during pregnancy due to possible teratogenic 
effect [33, 34]. 
Gamma lenolenic acid (GLA): An essential polyunsaturated 
fatty acid is present in large quantities in evening prim- rose oil. 
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Women with cyclical mastalgia have been found to have low levels 
of the metabolites of GLA in the plasma. A multicenter study 
randomized patients into four groups: (1) GLA and antioxidants, 
(beta carotene, vitamin c, vitamin B6, zinc, and niacin); (2) 
placebo, fatty acid, and antioxidants; (3) GLA and placebo 
antioxidants; and (4) placebo fatty acids. The investigators 
concluded that GLA efficacy was similar to placebo, regardless of 
whether antioxidant vitamins were added or not [35]. 
Bromocriptine: It is a dopamine agonist and stimulates the 
dopaminergic receptors in the anterior pituitary and blocks the 
release of prolactin. It is administered at a dose of 2.5 mg twice 
daily, about 47 to 88 % of patients are reported to have a significant 
long-lasting relief in breast pain. In a meta-analysis, bromocriptine 
was found to offer a reduction in mean pain score of 16.31 as 
compared to placebo [22]. Most mastalgia experts have stopped 
using bromocriptine because of severe side effects, the commonest 
being nausea, vomiting, and dizziness. 
Lisuride maleate: It is an ergot derivative. It is a dopamine 
agonist which binds to prolactin receptors. A double blind placebo-
controlled randomized study evaluated lisuride therapy for 
mastalgia at a dose of 0.2 mg/day and found it to be an effective 
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and well-tolerated treatment. Its key advantage over bromocriptine 
is the lower prevalence of side effects with lisuride [36]. It is not 
widely used and should be used with caution as it has been 
associated with pathological gambling and hypersexuality.  
Goserelin (LHRH analog): Goserelin in a placebo- controlled 
randomized trial of 147 premenopausal cases showed a significant 
reduction in mean days with severe pain from 17.6 to 5.9, i.e., 67 % 
reduction [37]. It is effective in recurrent mastalgia and mastalgia 
not responding to other hormonal therapies. 
Trigger point pain: In some women, pain is localized to one 
tiny spot of the breast. If imaging of breast does not reveal any 
organic lesion, this trigger point may be treated by injection of 
lignocaine 2 % (2 ml) followed by an injection of long-acting 
steroid (e.g., triamcinalone acetate 1 ml solution). 
Surgery: There is very limited role for surgery in treat- ment 
of mastalgia. Surgery can be useful in selected patients with a 
discrete, small trigger spot whose symp- toms may be relieved by 
excision of spot [38]. For generalized mastalgia, mastectomy is not 
advised. If patient insist on mastectomy, a careful psychological 
assessment is advised prior to agreeing to surgery [39]. Patients 
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should be informed of possible complications inherent of 
reconstructive surgery and warned that in 50 % cases their pain will 
not be improved [40]. Decision of surgery in mastalgia is a bilateral 
one after extremely careful and repeated observations usually on 
the insistence of the patient. 
EMBRYOLOGY OF BREAST  
At the fifth or sixth week of fetal development, two ventral 
bands of thickened ectoderm (mammary ridges, milk lines) are 
evident in the embryo.41 In most mammals, paired breasts develop 
along these ridges, which extend from the base of the forelimb 
(future axilla) to the region of the hind limb (inguinal area). These 
ridges are not prominent in the human embryo and disappear after a 
short time, except for small portions that may persist in the pectoral 
region.  
Each breast develops when an ingrowth of ectoderm forms a 
primary tissue bud in the mesenchyme. The primary bud, in turn, 
initiates the development of 15 to 20 secondary buds. Epithelial 
cords develop from the secondary buds and extend into the 
surrounding mesenchyme. Major (lactiferous) ducts develop, which 
open into a shallow mammary pit. During infancy, a proliferation of 
mesenchyme transforms the mammary pit into a nipple. The breast 
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remains undeveloped in the female until puberty, when it enlarges 
in response to ovarian estrogen and progesterone, which initiate 
proliferation of the epithelial and connective tissue elements. 
However, the breasts remain incompletely developed until 
pregnancy occurs. 
FIG 4. MILK LINES 
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FUNCTIONAL ANATOMY OF BREAST 
The breast is composed of 15 to 20 lobes which are each 
composed of several lobules.42 Fibrous bands of connective tissue 
travel through the breast (Cooper's suspensory ligaments), insert 
perpendicularly into the dermis, and provide structural support. The 
mature female breast extends from the level of the second or third 
rib to the inframammary fold at the sixth or seventh rib. It extends 
transversely from the lateral border of the sternum to the anterior 
axillary line. The deep or posterior surface of the breast rests on the 
fascia of the pectoralis major, serratus anterior, and external 
oblique abdominal muscles, and the upper extent of the rectus 
sheath. The retromammary bursa may be identified on the posterior 
aspect of the breast between the investing fascia of the breast and 
the fascia of the pectoralis major muscles. The axillary tail of 
Spence extends laterally across the anterior axillary fold. The upper 
outer quadrant of the breast contains a greater volume of tissue than 
do the other quadrants. The breast has a protuberant conical form. 
The base of the cone is roughly circular, measuring 10 to 12 cm in 
diameter. Considerable variations in the size, contour, and density 
of the breast are evident among individuals. 
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nulliparous breast has a hemispheric configuration with 
distinct flattening above the nipple. With the hormonal stimulation 
that accompanies pregnancy and lactation, the breast becomes 
larger and increases in volume and density, whereas with 
senescence, it assumes a flattened, flaccid, and more pendulous 
configuration with decreased volume. 
FIG 5. ANATOMY OF BREAST 
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NIPPLE-AREOLA COMPLEX 
The epidermis of the nipple-areola complex is pigmented and 
is variably corrugated. During puberty, the pigment becomes darker 
and the nipple assumes an elevated configuration. During 
pregnancy, the areola enlarges and pigmentation is further 
enhanced. The areola contains sebaceous glands, sweat glands, and 
accessory glands, which produce small elevations on the surface of 
the areola (Montgomery's tubercles). Smooth muscle bundle fibers, 
which lie circumferentially in the dense connective tissue and 
longitudinally along the major ducts, extend upward into the nipple, 
where they are responsible for the nipple erection that occurs with 
various sensory stimuli. The dermal papilla at the tip of the nipple 
contains numerous sensory nerve endings and Meissner's 
corpuscles. This rich sensory innervation is of functional 
importance, because the sucking of the infant initiates a chain of 
neurohumoral events that results in milk letdown. 
INACTIVE AND ACTIVE BREAST 
Each lobe of the breast terminates in a major (lactiferous) 
duct (2 to 4 mm in diameter), which opens through a constricted 
orifice (0.4 to 0.7 mm in diameter) into the ampulla of the nipple. 
Immediately below the nipple-areola complex, each major duct has 
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a dilated portion (lactiferous sinus), which is lined with stratified 
squamous epithelium. Major ducts are lined with two layers of 
cuboidal cells, whereas minor ducts are lined with a single layer of 
columnar or cuboidal cells. Myoepithelial cells of ectodermal origin 
reside between the epithelial cells in the basal lamina and contain 
myofibrils. In the inactive breast, the epithelium is sparse and 
consists primarily of ductal epithelium. In the early phase of the 
menstrual cycle, minor ducts are cord-like with small lumina. With 
estrogen stimulation at the time of ovulation, alveolar epithelium 
increases in height, duct lumina become more prominent, and some 
secretions accumulate. When the hormonal stimulation decreases, 
the alveolar epithelium regresses. With pregnancy, the breast 
undergoes proliferative and developmental maturation. 
As the breast enlarges in response to hormonal stimulation, 
lymphocytes, plasma cells, and eosinophils accumulate within the 
connective tissues. The minor ducts branch and alveoli develop. 
Development of the alveoli is asymmetric, and variations in the 
degree of development may occur within a single lobule. With 
parturition, enlargement of the breasts occurs via hypertrophy of 
alveolar epithelium and accumulation of secretory products in the 
lumina of the minor ducts. Alveolar epithelium contains abundant 
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endoplasmic reticulum, large mitochondria, Golgi complexes, and 
dense lysosomes. Two distinct substances are produced by the 
alveolar epithelium: (a) the protein component of milk, which is 
synthesized in the endoplasmic reticulum (merocrine secretion); 
and (b) the lipid component of milk (apocrine secretion), which 
forms as free lipid droplets in the cytoplasm. Milk released in the 
first few days after parturition is called colostrum and has low lipid 
content but contains considerable quantities of antibodies. The 
lymphocytes and plasma cells that accumulate within the 
connective tissues of the breast are the source of the antibody 
component. With subsequent reduction in the number of these cells, 
the production of colostrum decreases and lipid-rich milk is 
released. 
 25 
FIG 6. ANATOMY OF BREAST-SAGITTAL SECTION 
 
BLOOD SUPPLY, INNERVATION, AND LYMPHATICS 
The breast receives its principal blood supply from (a) 
perforating branches of the internal mammary artery; (b) lateral 
branches of the posterior intercostal arteries; and (c) branches from 
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the axillary artery, including the highest thoracic, lateral thoracic, 
and pectoral branches of the thoracoacromial artery. The second, 
third, and fourth anterior intercostal perforators and branches of the 
internal mammary artery arborize in the breast as the medial 
mammary arteries. The lateral thoracic artery gives off branches to 
the serratus anterior, pectoralis major and pectoralis minor, and 
subscapularis muscles. It also gives rise to lateral mammary 
branches. The veins of the breast and chest wall follow the course 
of the arteries, with venous drainage being toward the axilla. The 
three principal groups of veins are (a) perforating branches of the 
internal thoracic vein, (b) perforating branches of the posterior 
intercostal veins, and (c) tributaries of the axillary vein. Batson's 
vertebral venous plexus, which invests the vertebrae and extends 
from the base of the skull to the sacrum, may provide a route for 
breast cancer metastases to the vertebrae, skull, pelvic bones, and 
central nervous system. Lymph vessels generally parallel the course 
of blood vessels. 
Lateral cutaneous branches of the third through sixth 
intercostal nerves provide sensory innervation of the breast (lateral 
mammary branches) and of the anterolateral chest wall. These 
branches exit the intercostal spaces between slips of the serratus 
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anterior muscle. Cutaneous branches that arise from the cervical 
plexus, specifically the anterior branches of the supraclavicular 
nerve, supply a limited area of skin over the upper portion of the 
breast. The intercostobrachial nerve is the lateral cutaneous branch 
of the second intercostal nerve and may be visualized during 
surgical dissection of the axilla. Resection of the intercostobrachial 
nerve causes loss of sensation over the medial aspect of the upper 
arm. 
FIG 7. BLOOD SUPPLY OF BREAST 
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The boundaries for lymph drainage of the axilla are not well 
demarcated, and there is considerable variation in the position of 
the axillary lymph nodes. The six axillary lymph node groups 
recognized by surgeons (are (a) the axillary vein group (lateral), 
which consists of four to six lymph nodes that lie medial or 
posterior to the vein and receive most of the lymph drainage from 
the upper extremity; (b) the external mammary group (anterior or 
pectoral group), which consists of five or six lymph nodes that lie 
along the lower border of the pectoralis minor muscle contiguous 
with the lateral thoracic vessels and receive most of the lymph 
drainage from the lateral aspect of the breast; (c) the scapular group 
(posterior or subscapular), which consists of five to seven lymph 
nodes that lie along the posterior wall of the axilla at the lateral 
border of the scapula contiguous with the subscapular vessels and 
receive lymph drainage principally from the lower posterior neck, 
the posterior trunk, and the posterior shoulder; (d) the central 
group, which consists of three or four sets of lymph nodes that are 
embedded in the fat of the axilla lying immediately posterior to the 
pectoralis minor muscle and receive lymph drainage both from the 
axillary vein, external mammary, and scapular groups of lymph 
nodes, and directly from the breast;  
 29 
 (e) the subclavicular group (apical), which consists of six to 
twelve sets of lymph nodes that lie posterior and superior to the 
upper border of the pectoralis minor muscle and receive lymph 
drainage from all of the other groups of axillary lymph nodes; and 
(f) the interpectoral group (Rotter's nodes), which consists of one to 
four lymph nodes that are interposed between the pectoralis major 
and pectoralis minor muscles and receive lymph drainage directly 
from the breast. The lymph fluid that passes through the 
interpectoral group of lymph nodes passes directly into the central 
and subclavicular groups. 
The lymph node groups are assigned levels according to their 
anatomic relationship to the pectoralis minor muscle. Lymph nodes 
located lateral to or below the lower border of the pectoralis minor 
muscle are referred to as level I lymph nodes, which include the 
axillary vein, external mammary, and scapular groups. Lymph 
nodes located superficial or deep to the pectoralis minor muscle are 
referred to as level II lymph nodes, which include the central and 
interpectoral groups. Lymph nodes located medial to or above the 
upper border of the pectoralis minor muscle are referred to as level 
III lymph nodes, which consist of the subclavicular group. 
 30 
The plexus of lymph vessels in the breast arises in the 
interlobular connective tissue and in the walls of the lactiferous 
ducts and communicates with the subareolar plexus of lymph 
vessels. Efferent lymph vessels from the breast pass around the 
lateral edge of the pectoralis major muscle and pierce the 
clavipectoral fascia, ending in the external mammary (anterior, 
pectoral) group of lymph nodes. Some lymph vessels may travel 
directly to the subscapular (posterior, scapular) group of lymph 
nodes. From the upper part of the breast, a few lymph vessels pass 
directly to the subclavicular (apical) group of lymph nodes. The 
axillary lymph nodes usually receive >75% of the lymph drainage 
from the breast. The rest is derived primarily from the medial 
aspect of the breast, flows through the lymph vessels that 
accompany the perforating branches of the internal mammary 
artery, and enters the parasternal (internal mammary) group of 
lymph nodes. 
 31 
FIG 8. INACTIVE BREAST 
 
FIG 9. ACTIVE BREAST 
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PHYSIOLOGY OF THE BREAST 
BREAST DEVELOPMENT AND FUNCTION 
Breast development and function are initiated by a variety of 
hormonal stimuli, including estrogen, progesterone, prolactin, 
oxytocin, thyroid hormone, cortisol, and growth hormone.43,44 
Estrogen, progesterone, and prolactin especially have profound 
trophic effects that are essential to normal breast development and 
function. Estrogen initiates ductal development, whereas 
progesterone is responsible for differentiation of epithelium and for 
lobular development. Prolactin is the primary hormonal stimulus 
for lactogenesis in late pregnancy and the postpartum period.  It 
upregulates hormone receptors and stimulates epithelial 
development. Figure 10 depicts the secretion of neurotrophic 
hormones from the hypothalamus, which is responsible for 
regulation of the secretion of the hormones that affect the breast 
tissues. The gonadotropins luteinizing hormone (LH) and follicle-
stimulating hormone (FSH) regulate the release of estrogen and 
progesterone from the ovaries. In turn, the release of LH and FSH 
from the basophilic cells of the anterior pituitary is regulated by the 
secretion of gonadotropin-releasing hormone (GnRH) from the 
hypothalamus. Positive and negative feedback effects of circulating 
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estrogen and progesterone regulate the secretion of LH, FSH, and 
GnRH. These hormones are responsible for the development, 
function, and maintenance of breast tissues. In the female neonate, 
circulating estrogen and progesterone levels decrease after birth and 
remain low throughout childhood because of the sensitivity of the 
hypothalamic-pituitary axis to negative feedback from these 
hormones. With the onset of puberty, there is a decrease in the 
sensitivity of the hypothalamic-pituitary axis to negative feedback 
and an increase in its sensitivity to positive feedback from estrogen. 
These physiologic events initiate an increase in GnRH, FSH, and 
LH secretion and ultimately an increase in estrogen and 
progesterone secretion by the ovaries, which leads to establishment 
of the menstrual cycle. At the beginning of the menstrual cycle, 
there is an increase in the size and density of the breasts, which is 
followed by engorgement of the breast tissues and epithelial 
proliferation. With the onset of menstruation, the breast 
engorgement subsides and epithelial proliferation decreases.  
PREGNANCY, LACTATION, AND SENESCENCE 
A dramatic increase in circulating ovarian and placental 
estrogens and progestins is evident during pregnancy, which 
initiates striking alterations in the form and substance of the breast. 
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43-45 The breast enlarges as the ductal and lobular epithelium 
proliferates, the areolar skin darkens, and the accessory areolar 
glands (Montgomery's glands) become prominent. In the first and 
second trimesters, the minor ducts branch and develop. During the 
third trimester, fat droplets accumulate in the alveolar epithelium 
and colostrum fills the alveolar and ductal spaces. In late 
pregnancy, prolactin stimulates the synthesis of milk fats and 
proteins. 
After delivery of the placenta, circulating progesterone and 
estrogen levels decrease, which permits full expression of the 
lactogenic action of prolactin. Milk production and release are 
controlled by neural reflex arcs that originate in nerve endings of 
the nipple-areola complex. Maintenance of lactation requires 
regular stimulation of these neural reflexes, which results in 
prolactin secretion and milk letdown.  
Oxytocin release results from the auditory, visual, and 
olfactory stimuli associated with nursing. Oxytocin initiates 
contraction of the myoepithelial cells, which results in compression 
of alveoli and expulsion of milk into the lactiferous sinuses. After 
weaning of the infant, prolactin and oxytocin release decreases. 
Dormant milk causes increased pressure within the ducts and 
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alveoli, which results in atrophy of the epithelium. With menopause 
there is a decrease in the secretion of estrogen and progesterone by 
the ovaries and involution of the ducts and alveoli of the breast. 
The surrounding fibrous connective tissue increases in density, and 
breast tissues are replaced by adipose tissues. 
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FIG 10. NEUROHUMORAL CONTROL OF BREAST 
FUNCTION 
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INFECTIOUS AND INFLAMMATORY DISORDERS OF THE 
BREAST 
Except during the postpartum period, infections of the breast 
are rare and are classified as intrinsic (secondary to abnormalities 
in the breast) or extrinsic (secondary to an infection in an adjacen t 
structure, e.g., skin, thoracic cavity).  
BACTERIAL INFECTION 
Staphylococcus aureus and Streptococcus species are the 
organisms most frequently recovered from nipple discharge from an 
infected breast. Breast abscesses are typically seen in 
staphylococcal infections and present with point tenderness, 
erythema, and hyperthermia. These abscesses are related to 
lactation and occur within the first few weeks of breastfeeding. The 
progression of a staphylococcal infection, which may result in 
subcutaneous, subareolar, interlobular (periductal), and 
retromammary abscesses (unicentric or multicentric), necessitating 
operative drainage of fluctuant areas. Preoperative ultrasonography 
is effective in delineating the required extent of the drainage 
procedure, which is best accomplished via circumareolar incisions 
or incisions paralleling Langer's lines.  
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Although staphylococcal infections tend to be more localized 
and may be situated deep in the breast tissues, streptococcal 
infections usually present with diffuse superficial involvement. 
They are treated with local wound care, including application of 
warm compresses, and the administration of IV antibiotics 
(penicillins or cephalosporins). Breast infections may be chronic, 
possibly with recurrent abscess formation. In this situation, cultures 
are performed to identify acid-fast bacilli, anaerobic and aerobic 
bacteria, and fungi. Uncommon organisms may be encountered, and 
long-term antibiotic therapy may be required. 
Biopsy of the abscess cavity wall is generally recommended 
at the time of incision and drainage to rule out underlying or 
coexisting breast cancer with necrotic tumor. 
Hospital-acquired puerperal infections of the breast are much 
less common nowadays, but nursing women who present with milk 
stasis or noninfectious inflammation may still develop this problem. 
Epidemic puerperal mastitis is initiated by highly virulent strains of 
methicillin-resistant S. aureus that are transmitted via the suckling 
neonate and may result in substantial morbidity and occasional 
mortality. 
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Purulent fluid may be expressed from the nipple. In this 
circumstance, breastfeeding is stopped, antibiotics are started, and 
surgical therapy is initiated. Nonepidemic (sporadic) puerperal 
mastitis refers to involvement of the interlobular connective tissue 
of the breast by an infectious process. The patient develops nipple 
fissuring and milk stasis, which initiate a retrograde bacterial 
infection. Emptying of the breast using breast suction pumps 
shortens the duration of symptoms and reduces the incidence of 
recurrences. The addition of antibiotic therapy results in a 
satisfactory outcome in >95% of cases. 
Zuska's disease, also called recurrent periductal mastitis, is a 
condition of recurrent retroareolar infections and abscesses.
48,49
 
This syndrome is managed symptomatically, by antibiotics coupled 
with incision and drainage as necessary. Attempts to obtain durable 
long-term control by wide débridement of chronically infected 
tissue and/or terminal duct resection are frequently frustrated by 
postoperative infections. Smoking has been implicated as a risk 
factor for this condition. 
MYCOTIC INFECTIONS 
Fungal infections of the breast are rare and usually involve 
blastomycosis or sporotrichosis.
47
 Intraoral fungi that are 
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inoculated into the breast tissue by the suckling infant initiate these 
infections, which present as mammary abscesses in close proximity 
to the nipple-areola complex. Pus mixed with blood may be 
expressed from sinus tracts. Antifungal agents can be administered 
for the treatment of systemic (noncutaneous) infections. This 
therapy generally eliminates the necessity of surgical intervention, 
but occasionally drainage of an abscess, or even partial 
mastectomy, may be necessary to eradicate a persistent fungal 
infection. Candida albicans affecting the skin of the breast presents 
as erythematous, scaly lesions of the inframammary or axillary 
folds. Scrapings from the lesions demonstrate fungal elements 
(filaments and binding cells). Therapy involves the removal of 
predisposing factors such as maceration and the topical application 
of nystatin. 
HIDRADENITIS SUPPURATIVA 
Hidradenitis suppurativa of the nipple-areola complex or 
axilla is a chronic inflammatory condition that originates within the 
accessory areolar glands of Montgomery or within the axillary 
sebaceous glands.
47
 Women with chronic acne are predisposed to 
developing hidradenitis. When located in and about the nipple-
areola complex, this disease may mimic other chronic inflammatory 
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states, Paget's disease of the nipple, or invasive breast cancer. 
Involvement of the axillary skin is often multifocal and contiguous. 
Antibiotic therapy with incision and drainage of fluctuant areas is 
appropriate treatment. Excision of the involved areas may be 
required. Large areas of skin loss may necessitate coverage with 
advancement flaps or split-thickness skin grafts. 
MONDOR'S DISEASE 
Mondor's disease is a variant of thrombophlebitis that 
involves the superficial veins of the anterior chest wall and breast.
50
 
In 1939, Mondor described the condition as "string phlebitis," a 
thrombosed vein presenting as a tender, cord-like structure.
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Frequently involved veins include the lateral thoracic vein, the 
thoracoepigastric vein, and, less commonly, the superficial 
epigastric vein. Typically, a woman presents with acute pain in the 
lateral aspect of the breast or the anterior chest wall. A tender, firm 
cord is found to follow the distribution of one of the major 
superficial veins. Rarely, the presentation is bilateral, and most 
women have no evidence of thrombophlebitis in other anatomic 
sites. This benign, self-limited disorder is not indicative of a 
cancer. When the diagnosis is uncertain, or when a mass is present 
near the tender cord, biopsy is indicated. Therapy for Mondor's 
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disease includes the liberal use of anti-inflammatory medications 
and application of warm compresses along the symptomatic vein. 
Restriction of motion of the ipsilateral extremity and shoulder as 
well as brassiere support of the breast are important. The process 
usually resolves within 4 to 6 weeks. When symptoms persist or are 
refractory to therapy, excision of the involved vein segment is 
appropriate. 
COMMON BENIGN DISORDERS AND DISEASES OF THE 
BREAST 
Benign breast disorders and diseases encompass a wide range 
of clinical and pathologic entities. Surgeons require an in-depth 
understanding of benign breast disorders and diseases so that clear 
explanations may be given to affected women, appropriate 
treatment instituted, and unnecessary long-term follow up avoided. 
ABERRATIONS OF NORMAL DEVELOPMENT AND 
INVOLUTION 
The basic principles underlying the aberrations of normal 
development and involution (ANDI) classification of benign breast 
conditions are the following: (a) benign breast disorders and 
diseases are related to the normal processes of reproductive life and 
to involution; (b) there is a spectrum of breast conditions that 
ranges from normal to disorder to disease; and (c) the ANDI 
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classification encompasses all aspects of the breast condition, 
including pathogenesis and the degree of abnormality.
52
 The 
horizontal component of Table 17-3 defines ANDI along a 
spectrum from normal, to mild abnormality (disorder), to severe 
abnormality (disease). The vertical component indicates the period 
during which the condition develops. 
TABLE 17-3 ANDI CLASSIFICATION OF BENIGN BREAST 
DISORDERS 
 Normal Disorder Disease 
Early 
reproductive 
years (age 15–
25 y)   
Lobular 
development 
Fibroadenoma Giant 
fibroadenoma 
Stromal 
development 
Adolescent 
hypertrophy 
Gigantomastia 
Nipple eversion Nipple 
inversion 
Subareolar 
abscess 
    Mammary duct 
fistula 
Later 
reproductive 
years (age 25–
40 y) 
Cyclical 
changes of 
menstruation 
Cyclical 
mastalgia 
Incapacitating 
mastalgia 
  Nodularity   
Epithelial 
hyperplasia of 
pregnancy 
Bloody nipple 
discharge 
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 Normal Disorder Disease 
Involution (age 
35–55 y)  
Lobular 
involution 
Macrocysts — 
  Sclerosing 
lesions 
  
Duct involution     
  Dilatation Duct ectasia Periductal 
mastitis 
  Sclerosis Nipple 
retraction 
— 
Epithelial 
turnover 
Epithelial 
hyperplasia 
Epithelial 
hyperplasia with 
atypia 
EARLY REPRODUCTIVE YEARS 
Fibroadenomas are seen predominantly in younger women 
aged 15 to 25 years.53 Fibroadenomas usually grow to 1 or 2 cm in 
diameter and then are stable but may grow to a larger size. Small 
fibroadenomas (1 cm in size) are considered normal, whereas larger 
fibroadenomas (3 cm) are disorders and giant fibroadenomas (>3 
cm) are disease. Similarly, multiple fibroadenomas (more than five 
lesions in one breast) are very uncommon and are considered 
disease. The precise etiology of adolescent breast hypertrophy is 
unknown. A spectrum of changes from limited to massive stromal 
hyperplasia (gigantomastia) is seen. Nipple inversion is a disorder 
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of development of the major ducts, which prevents normal 
protrusion of the nipple. Mammary duct fistulas arise when nipple 
inversion predisposes to major duct obstruction, leading to 
recurrent subareolar abscess and mammary duct fistula.  
LATER REPRODUCTIVE YEARS 
Cyclical mastalgia and nodularity usually are associated with 
premenstrual enlargement of the breast and are regarded as normal. 
Cyclical pronounced mastalgia and severe painful nodularity are 
viewed differently than are physiologic discomfort and lumpiness. 
Painful nodularity that persists for >1 week of the menstrual cycle 
is considered a disorder. In epithelial hyperplasia of pregnancy, 
papillary projections sometimes give rise to bilateral bloody nipple 
discharge. 
INVOLUTION 
Involution of lobular epithelium is dependent on the 
specialized stroma around it. However, an integrated involution of 
breast stroma and epithelium is not always seen, and disorders of 
the process are common. When the stroma involutes too quickly, 
alveoli remain and form microcysts, which are precursors of 
macrocysts. Macrocysts are common, are often subclinical, and do 
not require specific treatment. Sclerosing adenosis is considered a 
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disorder of both the proliferative and the involutional phases of the 
breast cycle. Duct ectasia (dilated ducts) and periductal mastitis are 
other important components of the ANDI classification. Periductal 
fibrosis is a sequela of periductal mastitis and may result in nipple 
retraction. Sixty percent of women 70 years of age exhibit some 
degree of epithelial hyperplasia. Atypical proliferative diseases 
include ductal and lobular hyperplasia, both of which display some 
features of carcinoma in situ. Women with atypical ductal or 
lobular hyperplasia have a fourfold increase in breast cancer risk 
(Table 17-4). 
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TABLE 17-4 CANCER RISK ASSOCIATED WITH BENIGN 
BREAST DISORDERS AND IN SITU CARCINOMA OF THE 
BREAST 
Abnormality Relative Risk 
Nonproliferative lesions of the breast No increased risk 
Sclerosing adenosis No increased risk 
Intraductal papilloma No increased risk 
Florid hyperplasia 1.5 to 2-fold 
Atypical lobular hyperplasia 4-fold 
Atypical ductal hyperplasia 4-fold 
Ductal involvement by cells of  
atypical ductal hyperplasia 
7-fold 
Lobular carcinoma in situ 10-fold 
Ductal carcinoma in situ 10-fold 
Source: Modified from Dupont WD, et al: Risk factors for 
breast cancer in women with proliferative breast disease. N Engl J 
Med 312:146, 1985. 
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TABLE 17-5 CLASSIFICATION OF BENIGN BREAST 
DISORDERS 
Nonproliferative disorders of the breast 
Cysts and apocrine metaplasia 
Duct ectasia 
Mild ductal epithelial hyperplasia 
Calcifications 
Fibroadenoma and related lesions 
Proliferative breast disorders without atypia 
Sclerosing adenosis 
Radial and complex sclerosing lesions 
Ductal epithelial hyperplasia 
Intraductal papillomas 
Atypical proliferative lesions 
Atypical lobular hyperplasia 
Atypical ductal hyperplasia 
Source: Modified from Consensus Meeting
29
 with permission. 
Copyright © American Medical Association. 
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PATHOLOGY OF NONPROLIFERATIVE DISORDERS 
Of paramount importance for the optimal management of 
benign breast disorders and diseases is the histologic differentiation 
of benign, atypical, and malignant changes.54,55 Determining the 
clinical significance of these changes is a problem that is 
compounded by inconsistent nomenclature. The classification 
system originally developed by Page separates the various types of 
benign breast disorders and diseases into three clinically relevant 
groups: nonproliferative disorders, proliferative disorders without 
atypia, and proliferative disorders with atypia (Table 17-5). 
Nonproliferative disorders of the breast account for 70% of benign 
breast conditions and carry no increased risk for the development of 
breast cancer. This category includes cysts, duct ectasia, periductal 
mastitis, calcifications, fibroadenomas, and related disorders  
Breast macrocysts are an involutional disorder, have a high 
frequency of occurrence, and are often multiple. Duct ectasia is a 
clinical syndrome characterized by dilated subareolar ducts that are 
palpable and often associated with thick nipple discharge. 
Haagensen regarded duct ectasia as a primary event that led to 
stagnation of secretions, epithelial ulceration, and leakage of duct 
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secretions (containing chemically irritating fatty acids) into 
periductal tissue.57  
This sequence was thought to produce a local inflammatory 
process with periductal fibrosis and subsequent nipple retraction. 
An alternative theory considers periductal mastitis to be the 
primary process, which leads to weakening of the ducts and 
secondary dilatation. It is possible that both processes occur and 
together explain the wide spectrum of problems seen, which include 
nipple discharge, nipple retraction, inflammatory masses, and 
abscesses. 
Calcium deposits are frequently encountered in the breast. 
Most are benign and are caused by cellular secretions and debris or 
by trauma and inflammation. Calcifications that are associated with 
cancer include microcalcifications, which vary in shape and density 
and are <0.5 mm in size, and fine, linear calcifications, which may 
show branching. Fibroadenomas have abundant stroma with 
histologically normal cellular elements. They show hormonal 
dependence similar to that of normal breast lobules in that they 
lactate during pregnancy and involute in the postmenopausal 
period. Adenomas of the breast are well circumscribed and are 
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composed of benign epithelium with sparse stroma, which is the 
histologic feature that differentiates them from fibroadenomas.  
They may be divided into tubular adenomas and lactating 
adenomas. Tubular adenomas are seen in young nonpregnant 
women, whereas lactating adenomas are seen during pregnancy or 
during the postpartum period. Hamartomas are discrete breast 
tumors that are usually 2 to 4 cm in diameter, firm, and sharply 
circumscribed. Adenolipomas consist of sharply circumscribed 
nodules of fatty tissue that contain normal breast lobules and duct. 
FIBROCYSTIC DISEASE  
The term fibrocystic disease is nonspecific. Too frequently, it 
is used as a diagnostic term to describe symptoms, to rationalize the 
need for breast biopsy, and to explain biopsy results. Synonyms 
include fibrocystic changes, cystic mastopathy, chronic cystic 
disease, chronic cystic mastitis, Schimmelbusch's disease, 
mazoplasia, Cooper's disease, Reclus' disease, and 
fibroadenomatosis. Fibrocystic disease refers to a spectrum of 
histopathologic changes that are best diagnosed and treated 
specifically. 
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PATHOLOGY OF PROLIFERATIVE DISORDERS WITHOUT 
ATYPIA 
Proliferative breast disorders without atypia include 
sclerosing adenosis, radial scars, complex sclerosing lesions, ductal 
epithelial hyperplasia, and intraductal papillomas.54,55 Sclerosing 
adenosis is prevalent during the childbearing and perimenopausal 
years and has no malignant potential. Histologic changes are both 
proliferative (ductal proliferation) and involutional (stromal 
fibrosis, epithelial regression). Sclerosing adenosis is characterized 
by distorted breast lobules and usually occurs in the context of 
multiple microcysts, but occasionally presents as a palpable mass. 
Benign calcifications are often associated with this disorder. 
Central sclerosis and varying degrees of epithelial proliferation, 
apocrine metaplasia, and papilloma formation characterize radial 
scars and complex sclerosing lesions of the breast. Lesions up to 1 
cm in diameter are called radial scars, whereas larger lesions are 
called complex sclerosing lesions. Radial scars originate at sites of 
terminal duct branching where the characteristic histologic changes 
radiate from a central area of fibrosis. All of the histologic features 
of a radial scar are seen in the larger complex sclerosing lesions, 
but there is a greater disturbance of structure with papilloma 
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formation, apocrine metaplasia, and occasionally sclerosing 
adenosis. 
Mild ductal hyperplasia is characterized by the presence of 
three or four cell layers above the basement membrane. Moderate 
ductal hyperplasia is characterized by the presence of five or more 
cell layers above the basement membrane. Florid ductal epithelial 
hyperplasia occupies at least 70% of a minor duct lumen. It is found 
in >20% of breast tissue specimens, is either solid or papillary, and 
is associated with an increased cancer risk (see Table 17-4). 
Intraductal papillomas arise in the major ducts, usually in 
premenopausal women. They generally are <0.5 cm in diameter but 
may be as large as 5 cm. A common presenting symptom is nipple 
discharge, which may be serous or bloody. Grossly, intraductal 
papillomas are pinkish tan, friable, and usually attached to the wall 
of the involved duct by a stalk. They rarely undergo malignant 
transformation, and their presence does not increase a woman's risk 
of developing breast cancer (unless accompanied by atypia). 
However, multiple intraductal papillomas, which occur in younger 
women and are less frequently associated with nipple discharge, are 
susceptible to malignant transformation. 
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PATHOLOGY OF ATYPICAL PROLIFERATIVE DISEASES 
The atypical proliferative diseases have some of the features 
of carcinoma in situ but either lack a major defining feature of 
carcinoma in situ or have the features in less than fully developed 
form.57 In 1978, Haagensen and colleagues described lobular 
neoplasia, a spectrum of disorders ranging from atypical lobular 
hyperplasia to lobular carcinoma in situ (LCIS).58 
TREATMENT OF SELECTED BENIGN BREAST 
DISORDERS AND DISEASES 
CYSTS 
Because needle biopsy of breast masses may produce artifacts 
that make mammography assessment more difficult, many 
radiologists prefer to image breast masses before performing needle 
biopsy.
59,60
 In practice, however, the first investigation of palpable 
breast masses is frequently needle biopsy, which allows for the 
early diagnosis of cysts. A 21-gauge needle attached to a 10-mL 
syringe is placed directly into the mass, which is fixed by fingers of 
the nondominant hand. The volume of a typical cyst is 5 to 10 mL 
but it may be 75 mL or more. If the fluid that is aspirated is not 
bloodstained, then the cyst is aspirated to dryness, the needle is 
removed, and the fluid is discarded, because cytologic examination 
of such fluid is not cost effective. After aspiration, the breast is 
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carefully palpated to exclude a residual mass. If one exists, 
ultrasound examination is performed to exclude a persistent cyst, 
which is reaspirated if present. If the mass is solid, a tissue 
specimen is obtained. When cystic fluid is bloodstained, 2 mL of 
fluid is taken for cytologic examination. The mass is then imaged 
with ultrasound and any solid area on the cyst wall is sampled by 
needle biopsy. The presence of blood is usually obvious, but in 
cysts with dark fluid, an occult blood test or microscopic 
examination will eliminate any doubt. The two cardinal rules of 
safe cyst aspiration are that (a) the mass must disappear completely 
after aspiration, and (b) the fluid must not be bloodstained. If either 
of these conditions is not met, then ultrasound with needle biopsy 
or pneumocystography can be performed. A simple cyst is rarely of 
concern, but a complex cyst may be the result of an underlying 
malignancy. A pneumocystogram is obtained by injecting air into 
the cyst and then obtaining a repeat mammogram. When this 
technique is used, the wall of the cyst cavity can be more carefully 
assessed for any irregularities. 
FIBROADENOMAS 
Removal of all fibroadenomas has been advocated 
irrespective of patient age or other considerations, and solitary 
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fibroadenomas in young women are frequently removed to alleviate 
patient concern. Yet most fibroadenomas are self-limiting and many 
go undiagnosed, so a more conservative approach is reasonable. 
Careful ultrasound examination with core-needle biopsy will 
provide for an accurate diagnosis. Ultrasonography may reveal 
specific features that are pathognomonic for fibroadenoma. In this 
situation a core-needle biopsy may not be necessary. Subsequently, 
the patient is counseled concerning the ultrasound and biopsy 
results, and excision of the fibroadenoma may be avoided. 
Cryoablation is an approved treatment for fibroadenomas of the 
breast. With short-term follow-up a significant percentage of 
fibroadenomas will decrease in size and will no longer be 
palpable.
61
 However, many will remain palpable, especially those 
larger than 2 cm. Therefore, women should be counseled that the 
options for treatment include surgical removal, cryoablation, or 
observation. 
SCLEROSING DISORDERS 
The clinical significance of sclerosing adenosis lies in its 
mimicry of cancer. It may be confused with cancer on physical 
examination, by mammography, and at gross pathologic 
examination. Excisional biopsy and histologic examination are 
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frequently necessary to exclude the diagnosis of cancer. The 
diagnostic work-up for radial scars and complex sclerosing lesions 
frequently involves stereoscopic biopsy. It usually is not possible to 
differentiate these lesions with certainty from cancer by 
mammographic features, so biopsy is recommended. The 
mammographic appearance of a radial scar or sclerosing adenosis 
(mass density with spiculated margins) will usually lead to an 
assessment that the results of a core-needle biopsy showing benign 
disease are discordant with the radiographic findings. Breast 
radiologists will therefore often forego image-guided needle biopsy 
of a lesion suspicious for radial scar and refer the case directly to a 
surgeon for wire localized excisional biopsy. 
PERIDUCTAL MASTITIS 
Painful and tender masses behind the nipple-areola complex 
are aspirated with a 21-gauge needle attached to a 10-mL syringe. 
Any fluid obtained is submitted for cytologic examination and for 
culture using a transport medium appropriate for the detection of 
anaerobic organisms. In the absence of pus, women are started on a 
combination of metronidazole and dicloxacillin while awaiting the 
results of culture. Antibiotics are then continued based on 
sensitivity tests. Many cases respond satisfactorily, but when 
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considerable purulent material is present, surgical treatment is 
recommended. Unlike puerperal abscesses, a subareolar abscess is 
usually unilocular and often is associated with a single duct system. 
Preoperative ultrasound will accurately delineate its extent. The 
surgeon may either undertake simple drainage with a view toward 
formal surgery, should the problem recur, or proceed with 
definitive surgery. In a woman of childbearing age, simple drainage 
is preferred, but if there is an anaerobic infection, recurrent 
infection frequently develops. Recurrent abscess with fistula is a 
difficult problem and may be treated by fistulectomy or by major 
duct excision, depending on the circumstances (Table 17-6). When 
a localized periareolar abscess recurs at the previous site and a 
fistula is present, the preferred operation is fistulectomy, which has 
minimal complications and a high degree of success. However, 
when subareolar sepsis is diffuse rather than localized to one 
segment or when more than one fistula is present, total duct 
excision is the most expeditious approach. The first circumstance is 
seen in young women with squamous metaplasia of a single duct, 
whereas the latter circumstance is seen in older women with 
multiple ectatic ducts. Age is not always a reliable guide, however, 
and fistula excision is the preferred initial procedure for localized 
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sepsis irrespective of age. Antibiotic therapy is useful for recurrent 
infection after fistula excision, and a 2- to 4-week course is 
recommended before total duct excision. 
TABLE 17-6 TREATMENT OF RECURRENT SUBAREOLAR 
SEPSIS 
Suitable for Fistulectomy Suitable for Total Duct Excision 
Small abscess localized to 
one segment 
Large abscess affecting >50% of the 
areolar circumference 
Recurrence involving the 
same segment 
Recurrence involving a different 
segment 
Mild or no nipple inversion Marked nipple inversion 
Patient unconcerned about 
nipple inversion 
Patient requests correction of nipple 
inversion 
Younger patient Older patient 
No discharge from other 
ducts 
Purulent discharge from other ducts 
No prior fistulectomy Recurrence after fistulectomy 
Source: Modified with permission from Hughes LE: The duct 
ectasia/periductal mastitis complex, in Hughes LE, et al (eds): 
Benign Disorders and Diseases of the Breast: Concepts and Clinical 
Management. London: WB Saunders, 2000, p 162. Copyright © 
Elsevier. 
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MATERIALS AND METHODS 
In this clinical study on women with mastalgia the data on 
these patients presenting to surgical outpatient department were 
collected after obtaining proper written informed consent from the 
patients or their guardians and analysed in comparison to the 
literature. The epidemiological parameters included in the study are 
age, body mass index, dietary habits, complaint of lumpiness of the 
breast, type of mastalgia whether cyclical or non-cyclical, 
menstrual habits and previous history of benign breast diseases. 
These patients undergo thorough breast examination and general 
examination and systematic examination and findings noted. 
Patients are classified by their age groups and body mass index 
calculated by obtaining weight in kilogram and height in meter. 
Dietary habits are classified as vegetarian or non-vegetarian but not 
noted about the frequency in which they consume meat. Complaint 
of lumpiness of one or both breasts was obtained and palpation of 
the breasts was carried out accordingly. Type of mastalgia is 
elicited by maintaining breast pain chart and relation to the mensus 
was noted as cyclical when it occurs 1-2 weeks prior to mensus and 
non-cyclical otherwise. Previous history of similar complaints in 
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the past including previous medical or surgical treatment for the 
same was noted. Married women with children were questioned 
about their breastfeeding practices and noted. Clinical breast 
examination findings were noted as absence of significant 
abnormality or lump or nodularity. Lump in the breast is 
investigated by international protocol of triple assessment by 
clinical, radiological and pathological means. All these patients 
who mostly present with fear of cancer are comforted with an 
ultrasound scan of the breast and axilla. These findings are noted as 
absence of significant abnormality or fibroadenoma, fibrocystic 
changes or abscess. Any patient with lump or nodularity detected 
by clinical or radiological means are subjected to fine needle 
aspiration cytology and reported as no abnormality detected or 
fibroadenoma or fibrocystic changes or abscess. Patients with 
abscess are offered immediate surgical treatment in the form of 
drainage and pus obtained is sent for culture and postoperative 
antibiotics accordingly. Lump in the breast that are more than 2 cm 
are excised and sent for histopathological examination. Other 
patients who are clinically and radiologically normal are treated 
with ascending order of reassurance, topical analgesics and breast 
support by sports brassieres, evening primrose oil and vitamins and 
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danazol guided by the patient’s response to each treatment. 
Response is noted in terms of visual analogue scores of breast pain. 
The data thus obtained in 100 patients as prospective observational 
study over a period of 3 months study duration are analysed for 
patterns and relations. 
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AGE AND MASTALGIA 
AGE 
NO. OF PATIENTS 
(n=100) 
PERCENTAGE 
15-20 39 39% 
21-25 32 32% 
26-30 13 13% 
30-35 9 9% 
36-40 5 5% 
41-45 2 2% 
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LUMP AND MASTALGIA 
LUMP NO.OF PATIENTS (n=100) PERCENTAGE 
PRESENT 33 33% 
ABSENT 67 67% 
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CYCLICITY OF MASTALGIA 
TYPE OF 
MASTALGIA 
NO. OF PATIENTS 
(n=100) 
PERCENTAGE 
CYCLICAL 37 37% 
NON-CYCLICAL 63 63% 
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MENSTRUATION AND MASTALGIA 
MENSTRUAL 
HABITS 
NO OF 
PATIENTS(n=100) 
PERCENTAGE 
REGULAR 73 73% 
IRREGULAR 27 27% 
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PREVIOUS BENIGN BREAST DISEASES 
HISTORY NO. OF PATIENTS PERCENTAGE 
PRESENT 35 35% 
ABSENT 65 65% 
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DIETARY HABITS 
DIET 
NO. OF PATIENTS 
(n=100) 
PERCENTAGE 
VEGETARIAN 23 23% 
NON-
VEGETARIAN 
77 77% 
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BREAST FEEDING AND MASTALGIA 
BREASTFEEDING 
NO. OF PATIENTS 
(n=100) 
PERCENTAGE 
GIVEN 39 39% 
NOT GIVEN 4 4% 
NOT APPLICABLE 57 57% 
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BODY MASS INDEX AND MASTALGIA 
BMI NO. OF PATIENTS (n=100) PERCENTAGE 
<20 15 15% 
20-24.9 21 21% 
25-30 39 39% 
30.1-35 23 23% 
>35 2 2% 
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CLINICAL EXAMINATION FINDING 
CLINICAL 
EXAMINATON 
NO. OF PATIENTS 
(n=100) 
PERCENTAGE 
NAD 67 67% 
LUMP 8 8% 
ABSCESS 2 2% 
NODULARITY 23 23% 
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ULTRASOUND FINDINGS 
USG FINDINGS NO. OF PATIENTS (n=100) PERCENTAGE 
NAD 65 65% 
FA 10 10% 
FC 23 23% 
ABSCESS 2 2% 
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FNAC FINDINGS 
FNAC 
FINDINGS 
NO. OF PATIENTS 
(n=100) 
PERCENTAGE 
NAD 65 65% 
FA 10 10% 
FC 23 23% 
ABSCESS 2 2% 
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TREATMENT 
TREATMENT 
NO. OF PATIENTS  
(n =100) 
PERCENTAGE 
REASSURANCE 16 16% 
TOP+BS 57 57% 
PRIM 15 15% 
DANAZOL 1 1% 
SURGERY 11 11% 
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DISCUSSION 
AGE AND MASTALGIA 
Mastalgia is most prevalent among women of reproductive 
age. The range of ages involved that are included in this study is 
between 15 and 45 years. The average age of patients presenting in 
our series is 23.8 years. The median age is 24 years. More than 72 
patients were younger than 25 years of age. 
The previous series published in Cardiff breast clinic 
highlights the fact that mastalgia is more a disease of women of 
reproductive age. The median age of their data was 36 years and 
their study population which included 212 women of age ranging 
between 12 and 51 years. 
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AGE 
(Years) 
OUR STUDY 
(n=100) 
CARDIFF CLINIC 
(n=100) 
MEDIAN 24 36 
RANGE 15-45 12-51 
In the Cardiff clinic study they also noticed when the onset of 
mastalgia is in early age the severity of illness tends to be more and 
persistent despite treatment measures. In our study the average 
duration of pain is more than 6 months and it is particularly high 
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among the women with previous history of pain in the past which 
corresponds to their observation. 
LUMP AND MASTALGIA 
Though mastalgia as a clinical condition is more prevalent 
than lump in the breast, it is the lump that is more worrisome in 
patient’s mind. It draws attention to the previously prevalent breast 
pain and make them to seek medical advice. Fear of cancer among 
women is more widespread and recent efforts from government to 
create awareness in this field also has given some fruitful results in 
terms of increase in number of women who present with early 
stages of breast cancer which render them curable by surgery and 
chemotherapy.  
Lump in the breast is the single most common presentation in 
carcinoma of the breast. Clinically it is possible to differentiate 
most of the cancerous lumps from the rest of it by its hard nature 
and involvement of skin or chest wall. Some of them presents by 
symptomatic metastatic deposits such as pathological fractures 
before drawing attention to the breast lump since they are not 
frequently associated with pain. 
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In a clinical study published in clinical obstetrics and 
gynaecology by Kelley et al breast lump is not one of a frequent 
association with breast pain in 350 patients and lumpiness as 
complained by the patients are mostly not of carcinomatous 
aetiology63. Lumpiness in our study is complained by 33% of 
patients and none of it was due to breast cancer as evaluated by 
international protocol of triple assessment of breast lumps by 
clinical, radiological and pathological methods. 
Lumpiness of breast Our study (n=100) Kelley et al (n=350) 
Present 33% 29% 
Malignant 0 0 
Though lumps in patients with breast pain are not associated 
with cancer it always advisable to take these as serious issues until 
malignancy is surely ruled out by appropriate investigations. This 
principle is followed since there is quite a few patients who present 
with lump and pain have their breast lumps for much longer 
duration than pain which is of recent onset. 
TYPE OF MASTALGIA 
Breast pain can be classified as cyclical and non-cyclical in 
relation to the menstrual cycle. Cyclical mastalgia is the one which 
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occurs 1-2 weeks prior to mensus. This pain is often bilateral and 
complained to involve diffusely the whole of the breast with 
occasional radiation to the upper arm and axilla. 
Non-cyclical mastalgia is the one that lacks specific relation 
to the menstrual cycles. Cyclical mastalgia is usually prevalent 
among women aged 30-40 years. 
It is found to be relieved with onset of mensus in about 22% 
of patients and being persistent in 65% of patients despite 
treatment. 
In a study by srivastav et al conducted in AIIMS non-cyclical 
mastalgia is slightly more prevalent than cyclical mastalgia in north 
Indian women. In our study too this trend in favour of non-cyclical 
breast pain is observed.64 
Type of breast 
pain 
Our study (n=100) Srivastav et al (n=250) 
Cyclical 37% 44% 
Non-cyclical 63% 56% 
Patients with non-cyclical mastalgia may experience 
spontaneous resolution among 50% of them but still others may 
pose serious clinical problem with futile efforts in treating them. 
 79 
MENSTRUATION AND MASTALGIA 
It is popularly believed when breast pain due to altered 
hormonal status in women due to engorgement and ductal dilatation 
is present it is logical that uterus function in relation to this 
hormonal disarray should also be altered which manifests as 
irregular menstrual cycles. But this is not supported by evidence as 
in our study most of the patients have regular menstrual cycles. In 
the study conducted at AIIMS by srivastav et al similar results were 
observed. 
Menstrual cycles Our study (n=100) Srivastav et al (n=250) 
Regular 73% 65% 
Irregular 27% 35% 
There is also no strong evidence in literature that menstrual 
habits has any correlation to breast cancer when regularity is taken 
into account though the total number of cycles in a female’s life is 
positively related to the disease risk. The regular cycles that is the 
feature in most of the females with breast pain is preceded by the 
pain in cases of cyclical mastalgia whereas it is difficult  to 
establish this connection in patients with irregular cycles.  
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PREVIOUS BENIGN BREAST DISEASES IN MASTALGIA 
Previous history of benign breast symptoms is a frequent 
association with the patients currently presenting with mastalgia. 
History of previous benign diseases for which patient has received 
medical or surgical treatment is elicited in our study which 
corresponds to this fact. In the study conducted in AIIMS by 
srivastav et al also gives the same impression. 64 
Previous breast 
disease 
Our study 
(n=100) 
Srivastav et al 
(n=250) 
Present 35% 40% 
Absent 65% 60% 
A positive association in 35% of patients is significant 
proportion and hence when a patient comes for treatment of any 
breast complaints one can expect her to consult again for mastalgia 
in a later date. Though this point needs further studies with longer 
duration of followup to come to a conclusion. It is also noticeable 
that previous history of treatment for benign breast diseases is a 
risk factor for breast cancer though it is conclusive that mastalgia 
even when positively associated with previous benign diseases is 
not a risk factor for cancer perse. 
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DIETARY HABITS IN MASTALGIA 
Dietary habits may play a role in causing breast pain though 
there is no strong evidence to rule in or rule out this argument and 
hence this factor is included in our study. Though most of the 
women participated in our study were non-vegetarians it is 
imperative to conduct large population based studies to come to a 
firm conclusion that non-vegetarian diet is a risk factor for breast 
pain. In the data published by srivastav et al from AIIMS in which 
most of the participants were vegetarians it was found that average 
breast pain scores were higher in non-vegetarian females. 
Diet Our study (n=100) Srivastav et al (n=250) 
Vegetarian 23 80 
Non-vegetarian 77 20 
In our study the average pain score is 2.7 and it is same 
among the vegetarian and non-vegetarians. So the previously 
quoted study might have some confounding factors. Vegetarian diet 
contains more fruits and vegetables which are rich sources for 
antioxidants and vitamins. Animal fat is associated with lots of 
non-communicable diseases ranging from ischemic heart disease to 
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cancer of the colon and breast but it is not sure whether this 
influences patients with breast pain. Hence there is no strong 
recommendation from this current study to advise women to give 
up their non-vegetarian dietary habits to get relieved of their breast 
pain, though they may reap other benefits. 
BREASTFEEDING AND MASTALGIA 
Breastfeeding is claimed to be one of the protective factor 
against breast cancer in women and hence our interest to look for 
any protection that it can offer against breastpain. In an 
epidemiological study from srivastav et al from AIIMS they say 
that there is no significant relation between feeding and breastpain. 
In our study too we can find similar results. Breastfeeding history 
was elicited and unmarried women and married but yet to deliver 
women were also included in the study. In our part of the world 
breastfeeding practices are strong and most of the mothers who 
participated in the study gave positive history for feeding and only 
4% of women have not given breastmilk. But this seemingly 
increased incidence of breast pain among breastfed mothers is 
attributable to the above mentioned cultural practice of south indian 
women. 
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Breastfeeding practices Our study Srivastav et al 
Given 39% 46% 
Not given 4% 32% 
Not applicable 57% 22% 
Hence there is no firm evidence to make a recommendation of 
breastfeeding as a protective factor for breast pain but it need not 
be withheld in these patients since there is equally lack of evidence 
that it may increase the pain. 
OBESITY AND MASTALGIA 
During modern times obesity has increased among indian 
women due to the adaptation of western dietary habits and this has 
increased the incidence of non-communicable diseases such heart 
disease and stroke. It is also notable that obesity is associated to 
breast and colonic cancer. In women with breast pain obesity is not 
associated to the extent that it can be a cause. Obesity is classified 
according to the body mass index which is calculated by the 
formula by dividing the weight in kilogram by square of height in 
meter. The normal BMI is a range of 19-24.9. The average BMI in 
our study is found to be 26.9. This is slightly higher than the 
recommended norms and whether this reflects the overall increase 
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in obesity among the community rather than the women with 
mastalgia is yet to be ascertained. But it is always recommended 
that obese women must attempt to reduce weight to prevent the 
increased risk that it pose on cardiovascular health of the 
individual. 
In our study only 36% of the women had normal BMI and 
64% of them had increased BMI to various degrees but extremely 
morbid obesity is unusual among women presenting to our hospital 
which may be due to the fact that this hospital caters to the 
economically downtrodden people. Obese women are found to have 
higher pain scores in our study but this need to be confirmed with 
further large population based studies. Response to treatment is 
similar to non-obese females and hence it is not a routine schedule 
in the treatment. 
CLINICAL EXAMINATION 
Any patient presenting with breast pain must undergo a 
thorough physical examination including cardiovascular, chest wall 
and both breasts. In our study patients with breast pain beyond 
general examination were also subjected to thorough palpation of 
both breasts. Most of the patients do not present with clinically 
detectable abnormalities in breasts in our study that is in 67% of 
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patients. In our study 8% patients were presenting with clinically 
detectable lump in breasts and 23% were presenting with nodularity 
in one or both breasts. 2% were presenting with abscess which were 
not related to lactation. In a study published from AIIMS by 
srivastav et al also similar results in terms of absence of clinically 
detectable abnormalities in significant proportion of patients
64
. 
 
Clinical finding Our study(n=100) Srivastav et al(n=250) 
NAD 67% 75% 
Abscess 2% - 
Lump 8% 5% 
Nodularity 23% 20% 
INVESTIGATIONS 
Patients were subjected to ultrasound examination and when 
significant abnormality is detected is subjected to fine needle 
aspiration cytology. Most of the patients with clinically normal 
breasts were also without any detectable abnormalities in 
ultrasound and only 2% exhibited nodularity in breasts that were 
undetectable clinically which proved to be fibroadenoma in FNAC. 
Ultrasound is highly sensitive in diagnosing fibroadenoma, abscess 
and fibrocystic disease. These findings correspond to the 
 86 
cytological diagnosis in almost all the patients. These results are 
similar as in the series presented  by srivastav et al
64
. 
Ultrasound Our study(n=100) Srivastav et al(n=250) 
NAD 65% 74% 
FA 10% 11% 
FC 23% 15% 
ABSCESS 2% - 
 
 
FNAC Our study(n=100) Srivastav et al(n=250) 
NAD 65% 74% 
FA 10% 11% 
FC 23% 15% 
Abscess 2% - 
TREATMENT 
Most of the patients with clinically and investigation wise 
normal were treated by simple reassurance that it is not cancer and 
it will resolve spontaneously in most of similar patients and 
reported good resolution in pain scores. Others benefit from simple 
analgesics topically and breast support by sports brassiers. 
Considerable few have benefitted from evening primrose oil and 
vitamins but this benefit in relation to placebo is questionable from 
other evidences in literature. Patients with fibroadenoma who 
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presents with clinically worrisome lumps undergone surgery by 
excision biopsy and specimen reviewed histopathologically were 
found to be so and freed of anxiety. Abscess in breasts were 
surgically drained and antibiotics postoperatively according to the 
culture reports. The average relief in terms of pain scores by the 
above mentioned treatment modalities was 1.74. This result is the 
one observed by another study published by srivastav et al
64
. 
Treatment Our study(n=100) Srivastav et al(n=250) 
Reassurance 16% 20% 
Top+bs 57% 55% 
Prim 15% 10% 
Danazol 1% - 
surgery 11% 15% 
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CONCLUSION 
1) Breast pain is mainly a clinical condition prevalent among 
females of reproductive age group. 
2) Lumpiness of one or both breasts is a frequently associated 
complaint which requires detailed clinical examination and 
investigations. 
3) Non-cyclical mastalgia is more prevalent than cyclical 
mastalgia among women in south India but it may need 
confirmation by further large population based studies.  
4) Most of the females with breast pain have regular menstrual 
cycles. 
5) Presence of previous breast complaints or treatment for them 
is often elicit able among these women.  
6) Most of these women are non-vegetarians but this may reflect 
the general population character rather than its association as 
causality. 
7) Breastfeeding does not seemingly protect against incidence of 
breast pain. 
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8) Breast pain may be more common among obese females but 
this fact needs further studies to confirm. 
9) Clinical examination is more relevant in terms of ruling out 
significant pathologies of breast such as cancer rather than as 
a diagnosing tool. In our study none of these patients showed 
cancer pointing to the fact that most of the cancerous lumps 
are painless. 
10) Triple assessment for any breast lump offers better diagnostic 
yield. 
Most of these women are successfully treated with simple 
medications or reassurance. A fraction with lumps or abscess may 
require surgical treatment. Anti-estrogen therapy is indicated in 
rare occasions.                                                                                                                                                                                                                                                                      
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DATA COLLECTION SHEET 
I. Patient particulars:   
Name                                        I.p.No./o.p.no.                                
Case No. 
Age                                  DOA    DOD                                                                            
Address 
Occupation: 
II.Chief complaints   (with duration) 
A. Breast pain 
B. Breast lump 
C. Other complaints 
PAST HISTORY 
HISTORY OF PREVIOUS OPERATION  
 
PERSONAL HISTORY  
Diet: 
Menstrual history: 
Marital history: 
EXAMINATION 
General: 
Height:  Weight:  Body Mass Index: 
Breast examination:  
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INVESTIGATIONS 
Radiological: 
        Ultrasound breast – 
         Mammogram- 
         Xray chest- 
Pathological: 
         Fine needle aspiration- 
         Core needle biopsy- 
TREATMENT 
         Reassurance 
         Oral NSAIDs 
         Topical NSAIDs 
         Centchroman 
         Danazol 
         Evening primrose oil 
         Surgery  
FOLLOWUP 
 23 
MASTERCHART 
1 lakshmi 35 4 3 cyc - - yes non-veg reg P2L2 YES 19.3 NAD NAD - NAD - TOP+BS 2 
2 selvarani 30 3 5 cyc + 5 NO non-veg reg P2L2 YES 18.7 FA FA - NAD FA SX 1 
3 saradha 32 5 2 cyc - - yes non-veg reg P3L3 YES 21.2 NAD NAD - NAD - TOP+BS 2 
4 ellammal 35 4 3 cyc - - yes VEG reg P2L2 YES 23 NAD FC - NAD FC PRIM 3 
5 malathi 36 3 6 non-c + 5 NO non-veg reg P2L2 yes 25.3 NAD NAD - NAD - TOP+BS 2 
6 pitchammal 33 2 10 cyc - - yes non-veg reg P2L2 YES 32 NAD NAD - NAD - TOP+BS 1 
7 selvi 33 1 36 non-c - - no non-veg reg P3L3 YES 19.8 NAD NAD - NAD - TOP+BS 0 
8 reeta 24 3 6 non-c - - no veg reg P2L2 YES 25.3 NAD NAD - NAD - TOP+BS 1 
9 manimegalai 20 3 5 non-c - - no non-veg reg P1L1 YES 23.1 NAD NAD - FIB - TOP+BS 1 
10 divya 21 2 3 non-c - - no non-veg reg P1L1 YES 26.4 NAD NAD - NAD - TOP+BS 1 
11 saroja 31 2 5 non-c - - no non-veg reg P2L2 YES 27.3 NAD NAD - NAD - TOP+BS 0 
12 anandhi 26 4 6 non-c - - yes non-veg reg P1L1 YES 29.1 NAD NAD - PNE - TOP+BS 1 
13 banu 20 3 5 non-c - - yes non-veg reg P0A1 YES 18.9 NAD NAD - NAD - TOP+BS 2 
14 kalaiselvi 19 2 8 non-c - - no veg reg - - 18 NAD NAD - NAD - RE 1 
15 poornima 30 5 2 cyc - - yes non-veg reg P3L3 YES 19.6 NAD NAD - NAD - RE 2 
16 somya 24 3 6 cyc + 3 yes non-veg reg P2L2 YES 23 FA FA - NAD FA SX 1 
17 sundari 21 2 2 non-c - - no non-veg reg P1L1 YES 22 NAD NAD - NAD - TOP+BS 0 
18 jalaja kumari 19 2 6 non-c - - no non-veg irr - - 20.6 NAD NAD - NAD - TOP+BS 1 
19 varalakshmi 34 3 9 non-c - - no non-veg irr P2L2 YES 21.6 NAD NAD - OST - TOP+BS 1 
20 haripriya 22 4 5 non-c - - yes veg reg P1L1 YES 23 NAD NAD - NAD - TOP+BS 0 
21 sudha 19 2 5 cyc + 2 no veg reg - - 18 FA FA - NAD FA SX 0 
22 jayashankari 20 2 6 cyc + 6 yes non-veg irr - - 19 FA FA - NAD FA SX 1 
23 selvi 16 2 5 cyc - - no non-veg reg - - 26.4 NAD NAD - NAD - PRIM 0 
24 sakunthala 31 4 4 non-c - - no non-veg irr P1L1 YES 24 NAD NAD - NAD - RE 2 
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25 venmathi 21 3 12 cyc - - no non-veg reg - - 26 NAD NAD - NAD - TOP+BS 1 
26 bhavani 23 5 6 non-c - - yes veg irr - - 35 NAD NAD - NAD - TOP+BS 1 
27 joyce 33 3 1 non-c - - yes veg reg P2L2 YES 32.3 NAD NAD - NAD - TOP+BS 1 
28 kamala 20 2 18 non-c - - no non-veg reg - - 31 NAD NAD - NAD - TOP+BS 2 
29 chandra 24 2 15 non-c + 2 no non-veg reg P1L1 YES 23 NOD FC - NAD FC SX 1 
30 devi 19 3 10 non-c + 3 no non-veg reg - - 20.3 FA FA - NAD FA SX 1 
31 selvi 25 4 6 cyc + 4 no non-veg reg P2L2 YES 24 NOD FC - NAD FC PRIM 3 
32 bharathi 18 2 5 cyc - - no non-veg reg - - 23.7 NAD NAD - NAD - TOP+BS 1 
33 sennyammal 30 3 4 cyc - - no non-veg reg - - 20 NOD NAD - NAD - TOP+BS 0 
34 mala 22 4 3 cyc - - yes non-veg irr P1L1 YES 19.3 NAD NAD - NAD - TOP+BS 2 
35 nivedha 26 3 4 cyc - - no non-veg irr P1L1 YES 18.8 NAD NAD - PTB - TOP+BS 1 
36 zaibunisha 26 2 12 non-c + 10 yes veg reg P2L2 YES 36 FA FA - NAD FA SX 1 
37 tamilselvi 25 2 13 cyc - - no veg reg P3L3 YES 30 NAD NAD - NAD - PRIM 0 
38 parameshwari 25 4 2 non-c + 2 yes non-veg reg P3L2 NO 29 BA BA - NAD BA SX 1 
39 vijayalakshmi 44 3 5 non-c - - no non-veg reg P2L2 YES 28.6 NAD NAD NAD NAD - RE 0 
40 jayammal 27 2 5 non-c - - no non-veg reg P1L1 YES 29 NAD NAD - NAD - TOP+BS 1 
41 nalini 20 2 5 non-c + 4 yes non-veg reg - - 30 NOD FC - NAD FC RE 1 
42 devika 22 3 6 non-c - - yes non-veg reg - - 35 NAD NAD - NAD - PRIM 1 
43 ranganayaki 27 5 4 non-c + 4 no non-veg reg P0A1 - 32 BA BA - NAD BA SX 0 
44 jebhasanthi 39 2 5 non-c - - no veg reg P2L1 NO 31.6 NAD NAD - NAD - TOP+BS 1 
45 malliga 40 2 20 cyc - - no veg reg P2L1 YES 30.8 NAD NAD NAD NAD - TOP+BS 1 
46 vijiyarani 25 3 6 cyc - - yes non-veg irr P1L1 YES 29.6 NAD NAD - NAD - RE 0 
47 jayasudha 26 2 5 non-c + 4 no non-veg reg P2L2 YES 28.9 NOD FC - NAD FC PRIM 1 
48 geetha 36 6 2 non-c + 2 no non-veg reg - - 27.3 NOD FC - NAD FC DAN 3 
49 indira 38 5 2 non-c - - no non-veg irr - - 27.8 NAD NAD - NAD - TOP+BS 3 
50 rajalakshmi 45 4 5 cyc + 4 no non-veg reg P2L1 NO 32 FA FA FA NAD FA SX 3 
51 damayanthi 20 2 6 non-c - - yes non-veg reg - - 34.1 NAD NAD - NAD - TOP+BS 1 
52 athira 21 2 5 cyc + 3 yes veg reg - - 31.6 NOD FC - NAD FC RE 0 
 25 
53 aparna 23 2 4 non-c - - no non-veg irr - - 29.4 NOD FC - NAD FC RE 1 
54 aarthi 25 2 8 cyc + 6 no non-veg reg P0 - 29.6 NOD FC - NAD FC PRIM 1 
55 aishwarya 24 2 5 cyc - - no veg reg - - 28.3 NAD NAD - NAD - TOP+BS 1 
56 abinaya 26 3 6 non-c - - no non-veg irr - - 26 NAD NAD - NAD - TOP+BS 1 
57 devapriya 22 2 6 non-c - - no non-veg reg - - 31 NAD NAD - NAD - TOP+BS 1 
58 deepa 23 2 11 non-c + 10 yes non-veg reg P1L1 YES 30.4 NOD FC - NAD FC TOP+BS 1 
59 aruna 24 3 15 non-c + 12 no non-veg irr P1L1 NO 30 NOD FC - PTB FC TOP+BS 1 
60 ambika 19 2 5 cyc - - yes non-veg reg - - 26 NAD NAD - NAD - RE 2 
61 arulmozhi 18 3 5 non-c - - no veg irr - - 23 NAD NAD - NAD - TOP+BS 1 
62 kanimozhi 17 2 6 non-c - - yes veg reg - - 24.1 NAD NAD - NAD - TOP+BS 1 
63 kalaiarasi 21 2 2 non-c - - no non-veg reg - - 28.9 NAD NAD - NAD - TOP+BS 1 
64 kaviya 23 3 5 non-c + 5 no non-veg reg P1L1 YES 19.8 NOD FC - NAD FC TOP+BS 1 
65 thenmozhi 19 2 9 non-c + 6 no non-veg reg - - 20 FA FA - NAD FA SX 1 
66 priyadarshini 16 3 6 cyc - - no non-veg reg - - 31 NAD NAD - NAD - PRIM 0 
67 deepadarshini 18 2 6 non-c - - no non-veg irr - - 36 NAD NAD - NAD - TOP+BS 1 
68 megha 26 2 5 cyc + 5 no non-veg reg P2L2 YES 40 NOD FC - NAD FC TOP+BS 1 
69 meenakshi 25 2 6 cyc - - yes non-veg reg P0 - 34.9 NAD NAD - NAD - PRIM 1 
70 archana 21 3 8 cyc + 6 no non-veg reg - - 29 NOD FC - NAD FC RE 1 
71 suguna 19 2 3 non-c - - yes non-veg reg - - 26 NAD NAD - NAD - TOP+BS 0 
72 shanmugapriya 22 2 7 non-c + 6 no veg irr - - 34 NOD FC - NAD FC RE 1 
73 sivapriya 21 2 6 non-c - - no non-veg reg P1L1 YES 32 NAD NAD - NAD - TOP+BS 0 
74 kavitha 35 3 4 cyc - - no non-veg irr P2L2 YES 30 NAD NAD - NAD - TOP+BS 1 
75 sindhuja 20 2 6 non-c - - yes non-veg reg - - 19 NAD NAD - NAD - PRIM 1 
76 padampriya 18 3 5 cyc + 5 no veg irr - - 18 NAD NAD - NAD - RE 0 
77 elavarasi 16 2 4 cyc - - no non-veg reg - - 32 NAD NAD - NAD - TOP+BS 1 
78 anitha 20 2 2 cyc + 1 no non-veg reg - - 34 NAD NAD - NAD - RE 0 
79 chitra 21 3 10 non-c - - yes non-veg reg P1L1 YES 30 NAD NAD - NAD - TOP+BS 0 
80 annam 20 3 5 non-c - - no non-veg reg - - 29 NAD NAD - NAD - TOP+BS 1 
 26 
81 sebastina 19 2 9 non-c + 8 yes non-veg reg - - 25 NOD FC - NAD FC RE 0 
82 rebecca 18 4 6 non-c - - yes non-veg reg - - 25.4 NAD NAD - NAD - TOP+BS 2 
83 kanchana 21 2 4 non-c + 4 no veg irr - - 30 NOD FC - NAD FC TOP+BS 1 
84 sneha 17 2 8 non-c - - no veg reg - - 29 NAD NAD - NAD - PRIM 2 
85 swathi 19 3 7 non-c + 6 no non-veg irr - - 26.3 NAD FC - NAD FC TOP+BS 1 
86 shilpa 18 2 9 cyc - - yes non-veg irr - - 19.3 NAD NAD - NAD - TOP+BS 2 
87 priyanka 16 2 6 non-c - - yes non-veg irr - - 21.6 NAD NAD - NAD - RE 1 
88 mary 20 2 12 cyc + 10 no non-veg reg - - 26.4 NAD NAD - NAD - TOP+BS 0 
89 nisha 23 3 10 non-c - - yes non-veg reg - - 23.5 NAD NAD - NAD - TOP+BS 2 
90 nandini 22 2 11 non-c - - no veg reg P1L1 YES 21.1 NOD NAD - NAD - PRIM 1 
91 shalini 19 2 6 non-c + 6 yes veg irr - - 35 NOD FC - NAD FC PRIM 2 
92 karpagam 18 2 9 non-c - - no veg irr - - 30 NAD NAD - NAD - TOP+BS 2 
93 roja 27 3 8 cyc + 8 no veg reg P0 - 32 NAD FA - NAD FA RE 1 
94 sridevi 19 4 7 cyc - - no non-veg reg - - 31 NOD FC - NAD FC PRIM 2 
95 sukanya 18 2 6 non-c - - no non-veg irr - - 34 NAD NAD - NAD - PRIM 0 
96 keerthana 17 3 6 non-c - - no non-veg irr - - 33 NAD FC - NAD FC TOP+BS 1 
97 mahalakshmi 16 2 6 non-c + 6 no non-veg irr - - 22 NOD FA - NAD FA TOP+BS 0 
98 durga 15 2 5 non-c - - no non-veg irr - - 19.9 NAD NAD - NAD - TOP+BS 2 
99 anupriya 20 3 8 cyc - - yes non-veg reg - - 36 NOD FC - NAD FC TOP+BS 2 
100 amaravathi 21 2 6 non-c - - yes non-veg reg P1L1 YES 30 NOD FC - NAD FC TOP+BS 1 
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